GDRX GoodRx Holdings, Inc.
GoodRx Holdings, Inc., together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices. It also offers other healthcare products and services, including subscription programs and pharma manufacturer solutions, as well as telehealth services through the GoodRx Care platform. In addition, the company provides healthcare products and solutions for dogs, cats, and other pets. It serves pharmacy benefit managers who manage formularies and prescription transactions, including establishing pricing between consumers and pharmacies. The company was founded in 2011 and is headquartered in Santa Monica, California.…
Industry Peers
Health Information ServicesKey Statistics
About GoodRx Holdings (NASDAQ: GDRX)
›
GoodRx Holdings (NASDAQ: GDRX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Health Information Services industry, part of the Healthcare sector, and reports about 697 employees.
The shares were at 2.920 USD on 20 November 2026, down 6.1% over 52 weeks. Its 52-week range is 1.770 USD to 3.885 USD: the price is 24.8% below the high and 65.0% above the low.
At a market capitalisation of 996.14M USD, it trades at 58.4 times trailing earnings and 8.3 times forward earnings. The median trailing P/E of its 15 largest Health Information Services peers is 39.9, a premium of 46% for GDRX.
GoodRx Holdings reports return on equity of 4.9%, an operating margin of 11.4% and revenue down 1.3% year over year.
Its debt exceeds its cash by 242.84M USD, a debt-to-equity ratio of 0.88. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 12 analysts cover the stock, with an average rating of Hold; their mean price target of 3.950 USD is 35.3% above the current price. The next earnings report is expected on 23 November 2026.